INBRAIN Neuroelectronics develops graphene-based neural interfaces for precision neurostimulation. The company's proprietary graphene microelectrodes offer superior signal fidelity, biocompatibility, and miniaturization compared to traditional metal electrodes. INBRAIN is the first company to bring graphene-based BCI technology into clinical trials. Applications span Parkinson's disease, epilepsy, and chronic pain. The company received a EUR 4M grant from Spain's PERTE Chip initiative in 2025 for graphene BCI development.